Briefing
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.
A post hoc analysis of CALGB/SWOG 80702 examined whether postoperative ctDNA, measured with Signatera, predicted survival with adjuvant celecoxib plus chemotherapy in stage III colon cancer.
- Design: Evidence level 2
- Assay: Signatera